GHK-Cu Dosage: What the Studies Actually Administered

There is no established dose for injectable GHK-Cu, and the reason is narrower and more checkable than "the research is thin." Our GHK-Cu evidence review establishes that no human trial of the injected or systemic form has ever been published or registered; our side-effects review establishes the same absence on the safety side. This article covers the question neither one answers: across every study that has put GHK-Cu into a dish, an animal, or a person, what amount was actually used — and what category of number is it?

The short answer is that GHK-Cu's literature contains three kinds of numbers, and not one of them is a human injectable dose. It contains molar concentrations in cell culture, milligram-per-kilogram rates in mice, and a cream percentage in two human trials. This article keeps those three tiers apart, because collapsing them is exactly how an unvalidated protocol gets manufactured.

The one place a dose-response curve has actually been measured — and it goes back down

The most dosing-relevant sentence in GHK-Cu's entire published record comes from a 1992 cell-culture study of normal human fibroblasts, and almost nobody selling the compound quotes it. Researchers incubated the cells with GHK-Cu and measured glycosaminoglycan synthesis, the collagen-adjacent output the compound's whole marketing story rests on. Their result: "GHK-Cu induced a dose-dependent increase of the synthesis of total GAGs secreted into the culture medium and those associated with the cell layer. The effect of GHK-Cu was biphasic with a maximal stimulation at 10(-9) to 10(-8) M. At higher concentrations, the rate of synthesis returned progressively to that of control cultures"¹.

Read that carefully, because it cuts against the instinct every dosing search brings with it. At the only tier of evidence where anyone has actually plotted GHK-Cu's dose-response curve, the curve is biphasic — it peaks in the low nanomolar range and then comes back down toward untreated control as concentration rises. More was not better; more was eventually the same as nothing. That is a cell-culture measurement in a dish, not an animal dose and emphatically not a human one, and it cannot be converted into either. But it is the one piece of real dose-response data this compound has, and its direction is the opposite of what "take a bit more and see" assumes.

What the animal injection studies actually administered

Three published studies have injected GHK-Cu into a live animal and reported what they gave. Read specifically for dose rather than for the outcomes our evidence review already covers:

• •Rats, intra-articular, 2015. Seventy-two rats undergoing anterior cruciate ligament reconstruction were "randomized to saline, 0.3 or 3 mg/ml GHK-Cu groups," with "post-operational intra-articular injections... given from week 2, once a week, for 4 weeks"². This is the single best-characterized injected GHK-Cu dosing schedule anywhere in the literature, and it still does not publish the number most people are looking for: the paper reports a CONCENTRATION in milligrams per milliliter, not an injected volume or a total milligram amount per animal. Even here, the milligrams delivered are not in the published record. The study's own conclusion also matters for how to read its dose: the measured benefit "could not last as treatment discontinued."
• •Mice, intraperitoneal, 2020 and 2022. Two independent pulmonology groups used the identical dosing scheme in different disease models — GHK-Cu "injected intraperitoneally at doses of 0.2, 2 and 20 μg/g/day" on alternate days, against cigarette-smoke emphysema in one study³ and bleomycin-induced pulmonary fibrosis in the other⁴. Micrograms per gram of body weight is the same unit as milligrams per kilogram, so the top of that range is 20 mg/kg/day, given every other day. It is worth being explicit about what that figure is not: a milligram-per-kilogram rate in a mouse does not transfer to a person by multiplying body weight. Interspecies dose translation requires validated allometric scaling, none has been published for GHK-Cu, and there is no human study of any injected dose to check such a conversion against even if one attempted it.

What the two human trials administered — both topical, and one doesn't say

GHK-Cu's two controlled human trials are the reason it looks better-studied than BPC-157 or TB-500. Read for dose, they add less than that reputation implies:

• •The 1992 venous stasis ulcer trial. Eighty-six evaluable patients were randomized among silver sulfadiazine 1% cream, "a biologically active tripeptide copper complex 0.4% cream formulation," or an inert vehicle placebo⁵. That 0.4% figure is the only published, controlled human GHK-Cu dose of any kind — and it is a topical cream concentration. The trial's own result: silver sulfadiazine "proved to statistically reduce the ulcer size" compared with the other two arms, and "there was no difference between the latter two treatments," meaning the 0.4% GHK-Cu cream performed no better than plain vehicle.
• •The 2006 laser-resurfacing trial. Thirteen patients completed a randomized comparison of post-CO2-laser skincare regimens "with or without GHK-Cu"⁶. Its published abstract never states a concentration, a quantity, or an application frequency. Blinded evaluators and computer analysis "found no statistically significant differences between groups for earlier resolution of erythema," and objective assessment "found no significant improvement in wrinkles or overall skin quality," though patient-reported satisfaction was significantly higher in the GHK-Cu group (P = .04).

A 2025 formulation-science review of topically applied GHK explains part of why even the topical dose question stays unsettled: despite the ingredient's ubiquity in anti-wrinkle products, "there is a surprising absence of clinical studies using them," and the peptide's hydrophilic, unstable nature makes skin penetration at an active concentration a genuine formulation problem rather than only a marketing one⁷. And a 2026 orthopedic review evaluating GHK-Cu for the musculoskeletal use case injectable versions are actually sold on states the systemic gap directly: "no clinical data support its use for musculoskeletal conditions"⁸.

The copper question a dosage page has to answer

GHK-Cu is not only a peptide. It is a peptide-copper complex, and any discussion of how much to inject is also a discussion of how much copper is being injected. PubChem lists copper tripeptide-1 with the molecular formula C14H23CuN6O4+ and a molecular weight of 402.92 g/mol — one copper atom per molecule⁹. Copper's atomic mass of about 63.5 therefore accounts for roughly 16% of the complex by mass, or about 158 micrograms of copper per milligram of GHK-Cu. That is this article's own arithmetic from the published molecular weight, stated so a reader can check it, and it is the only quantitative statement about copper load anyone can make without knowing a dose.

The obvious next question is whether there is a ceiling to compare that against, and the honest answer is that the only published ceiling does not apply. The NIH Office of Dietary Supplements gives the adult Tolerable Upper Intake Level for copper as 10,000 micrograms per day — but its own framing is explicit about what that number covers: "The FNB has established ULs for copper from food and supplements for healthy individuals based on levels associated with liver damage," and, separately, "the ULs do not apply to individuals who are receiving supplemental copper under medical supervision"¹⁰. That is a dietary and oral-supplement intake limit, derived from oral exposure and hepatic outcomes. It is not a parenteral limit, it was never constructed to govern an injected route that bypasses intestinal copper absorption and its regulatory controls entirely, and citing it as if it reassured anyone about an injectable dose would be exactly the kind of cross-route borrowing this site's GHK-Cu coverage exists to refuse.

What is known about where an injected dose goes

One pharmacokinetic study of this molecule exists, and it is worth knowing precisely what it is. A 1997 analytical-chemistry paper developed a chromatography method for measuring GHK and its metabolite in plasma, then "applied to the pharmacokinetic study of GHK after a single dose was administered intravenously to rats"¹¹. Its finding, in full: "GHK was rapidly degraded to HK, which was eliminated rapidly."

Three qualifications belong on that sentence. It is a rat study, not a human one. It measured GHK, the bare tripeptide, rather than the copper complex sold as GHK-Cu. And it is a method-development paper, so its pharmacokinetic component is a demonstration of the assay rather than a dose-ranging program. No human pharmacokinetic study of GHK or GHK-Cu, by any route, was located for this article. That means nobody has published what blood level any injected dose produces in a person, how long it lasts, or how quickly it clears — the foundational measurements a dosing interval is normally built from.

Why there is no GHK-Cu dosing chart on this page

The regulatory picture, re-checked

DailyMed's structured-product-label search for "copper peptide" returns exactly three results, re-verified for this article on 2026-08-07 and unchanged from this site's earlier checks: two face serums and one hair-growth serum, all cosmetic products listing copper tripeptide-1 as one ingredient among several¹². No FDA-approved GHK-Cu drug product exists in any form, which means no agency-reviewed label anywhere carries a dose, a concentration, a frequency, or a maximum for this compound. Injectable GHK-Cu's own Pharmacy Compounding Advisory Committee hearing — the process that has already produced recommendations for BPC-157, TB-500, KPV, and MOTS-c — has not yet been held; as our evidence review documents, it is scheduled for before the end of February 2027.

What this means if you're looking for a GHK-Cu dose

There is no validated GHK-Cu dosing schedule for injection or any systemic route, and the gap is not a matter of the research being early — it is that the three tiers of number the literature does contain are each the wrong kind. The cell-culture data gives a molar concentration in a dish, and its own dose-response curve peaks in the low nanomolar range and then declines. The animal data gives an intra-articular concentration in rats (with the total milligrams never published) and an intraperitoneal milligram-per-kilogram rate in mice that cannot be scaled to a person without validated allometry nobody has published. The human data gives a single topical cream percentage from a 1992 trial in which that cream did not beat placebo, plus a 2006 trial that never states its concentration at all. And the only pharmacokinetic work is a rat assay-development study reporting rapid degradation of the bare peptide.

Numbers circulating on vendor pages and forums that describe a "typical" GHK-Cu injection are not traceable to any of the studies above — this article checked each one directly, and none of them supports a human injectable figure. Our GHK-Cu reconstitution calculator will do vial-to-syringe arithmetic on a number you already have from elsewhere, without validating that number against anything published, because there is nothing published to validate it against. For safety by route, see our GHK-Cu side-effects review; for the full efficacy picture, our evidence review; and for a reader who has decided to buy the compounded injectable form anyway, our GHK-Cu provider comparison reads pharmacy sourcing and standing price off each seller's own site.

For the same non-recommendation method applied to GHK-Cu's peptide-market neighbors, see our BPC-157 dosage article, our TB-500 dosage and side-effects review, and our KPV dosage article — that last one documents the closest parallel to this article's central finding, a foundational literature whose own papers decline to publish a dose. For two more non-peptide compounds where the dosing record splits sharply by route, see our NAD+ dosage article and our glutathione dosage article. And for the specific reason many people search for topical copper peptides in the first place, see loose skin after rapid GLP-1 weight loss.